Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aileron Therapeutics Inc ALRN

Healthcare Biotechnology
Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib... see more

Recent & Breaking News (NDAQ:ALRN)

71 Biggest Movers From Yesterday

Benzinga.com  February 15, 2019

52 Stocks Moving In Thursday's Mid-Day Session

Benzinga.com  February 14, 2019

58 Biggest Movers From Yesterday

Benzinga.com  January 17, 2019

Mid-Afternoon Market Update: Dow Rises 200 Points; First Data Shares Spike Higher

Benzinga.com  January 16, 2019

Aileron Therapeutics Commences Enrollment in a Phase 2a Expansion Cohort for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers

GlobeNewswire January 16, 2019

The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

Benzinga.com  December 19, 2018

The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan

Benzinga.com  December 18, 2018

The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch

Benzinga.com  December 14, 2018

Aileron Presents Interim ALRN-6924 Data from PTCL, MDS, and AML Clinical Trials at the 60th Annual American Society of Hematology Meeting

GlobeNewswire December 4, 2018

Aileron Enters Clinical Trial Collaboration with Pfizer to Evaluate ALRN-6924 in Combination with IBRANCE® (palbociclib) in MDM2-Amplified Cancers

GlobeNewswire November 27, 2018

Recent Analysis Shows Arcimoto, ADOMANI, Lipocine, Aileron Therapeutics, Allena Pharmaceuticals, and Perma-Fix Environmental Services Market Influences — Renewed Outlook, Key Drivers of Growth

GlobeNewswire November 19, 2018

Aileron Therapeutics Reports Third Quarter 2018 Financial Results

GlobeNewswire November 7, 2018

Aileron Therapeutics Appoints Vojislav Vukovic, MD, PhD, as Chief Medical Officer

GlobeNewswire November 5, 2018

The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Benzinga.com  November 4, 2018

Aileron Therapeutics Announces Clinical Trial Collaboration with Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

GlobeNewswire November 1, 2018

Aileron Therapeutics to Report Third Quarter 2018 Financial Results on November 7, 2018

GlobeNewswire October 30, 2018

Aileron Announces Poster Presentations at Two Scientific Conferences in November

GlobeNewswire October 19, 2018

48 Biggest Movers From Yesterday

Benzinga.com  October 17, 2018

Aileron Therapeutics Announces the Appointment of Dr. Manuel Aivado as Chief Executive Officer

GlobeNewswire September 6, 2018

Aileron Therapeutics Reports Second Quarter 2018 Financial Results

GlobeNewswire August 7, 2018